34 / 38
33
33
Diretrizes AMB
REFERÊNCIAS
1
.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera
R, et al.: International consensus statement on an update to the
classification for definite antiphospholipid syndrome (APS). J
Thromb Haemost 2006;4:295-306.
2. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of
secondary thromboprophylaxis in patients with antiphospholipid
antibodies. Arthritis Rheum 2007;57:1487-95.
3. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato
S, et al. Risk factors for a first thrombotic event in antiphospholipid
antibody carriers: a prospective multicenter follow-up study. Ann
Rheum Dis 2011;70:1083-6.
4. Cuadrado MJ, Bertolaccini ML, Seed P, Tektonidou M, Aguirre A,
Mico L, et al. Primary prevention of thrombosis in Antiphospholipid
Antibodies Positive patients: a prospective, multicenter, randomised,
open trial comparing low dose aspirin with low dose aspirin plus low
intensity oral anticoagulation [abstract]. Arthritis Rheum 2009;60
Suppl 10 :1285.
5. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E.
Analysis of risk factors for the development of thrombotic
complications in antiphospholipid antibody positive lupus patients.
Lupus 2007;16:39-45.
6. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M, Bertero
MT, et al. Risk factors for a first thrombotic event in antiphospholipid
antibody carriers. A multicentre, retrospective follow-up study. Ann
Rheum Dis 2009;68:397-9.
7. Hereng T, Lambert M, Hachulla E, Samor M, Dubucquoi S, Caron
C, et al. Influence of aspirin on the clinical outcomes of 103 anti-
phospholipid antibodies-positive patients. Lupus 2008;17:11-5.
8. Erkan D, Harrison MJ, Levy RA, Peterson M, Petri M, Sammaritano
L, et al. Aspirin for primary thrombosis prevention in the
antiphospholipid syndrome: a randomized, double-blind, placebo-
controlled trial in asymptomatic antiphospholipid antibody-positive
individuals. Arthritis Rheum 2007;56:2382-91.